Phase 3 Readout~month
Phase 3 Topline: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of C
- Company
- ASTRAZENECA PLC (AZN)
- Drug
- durvalumab
- Indication
- Non Small Cell Lung Carcinoma NSCLC
Other upcoming events for AZN
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Inves
Phase 3 ReadoutPhase 3 Topline: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulves
Phase 1 StartPhase 1 Start: A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokin
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety
Phase 1 StartPhase 1 Start: A Phase I, Open-label Study to Assess the Absorption, Distribution, Metabolism, and Excretion (ADME)
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.